A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer

被引：0
作者：
Sara M. Balch
Ines Vaz-Luis
Tianyu Li
Nabihah Tayob
Esha Jain
Karla Helvie
Jorge E. Buendia-Buendia
Erin Shannon
Steven J. Isakoff
Nadine M. Tung
Ian E. Krop
Nancy U. Lin
Nikhil Wagle
Rachel A. Freedman
机构：
[1] The Broad Institute of MIT and Harvard,Department of Data Sciences
[2] Department of Medical Oncology,undefined
[3] Dana-Farber Cancer Institute,undefined
[4] Institut Gustave Roussy,undefined
[5] Unit INSERM 981,undefined
[6] Dana-Farber Cancer Institute,undefined
[7] Massachusetts General Hospital,undefined
[8] Harvard Medical School,undefined
[9] Beth Israel Deaconess Medical Center,undefined
[10] Cellarity,undefined
[11] Inc.,undefined
来源：
Breast Cancer Research and Treatment | 2021年 / 189卷
关键词：
HER2+ breast cancer; Trastuzumab; Pertuzumab; Eribulin mesylate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：411 / 423
页数：12
相关论文
共 50 条
[21]   Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer [J].
Chung, Clement ;
Lam, Masha S. H. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (18) :1579-1587
[22]   Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer [J].
Bines, Jose ;
Procter, Marion ;
Restuccia, Eleonora ;
Viale, Giuseppe ;
Zardavas, Dimitrios ;
Suter, Thomas ;
Arahmani, Amal ;
Van Dooren, Veerle ;
Baselga, Jose ;
Clark, Emma ;
Eng-Wong, Jennifer ;
Gelber, Richard D. ;
Piccart, Martine ;
Mobus, Volker ;
de Azambuja, Evandro .
CLINICAL BREAST CANCER, 2020, 20 (02) :174-+
[23]   Investigating the Efficacy and Safety of a Dose-Dense Paclitaxel, Cyclophosphamide With Trastuzumab in Stage I-II Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer [J].
Elsayed, Lina ;
Reed, Elizabeth ;
Modi, Shivani ;
Tandra, Pavan K. ;
Copur, Mehmet S. ;
Samson, Kaeli ;
Krishnamurthy, Jairam .
CLINICAL BREAST CANCER, 2024, 24 (08) :676-682.e1
[24]   Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2) [J].
Seyedmirzaei, Homa ;
Keshavarz-Fathi, Mahsa ;
Razi, Sepideh ;
Gity, Masoumeh ;
Rezaei, Nima .
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (05) :1235-1244
[25]   Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer [J].
Mukai, Hirofumi ;
Saeki, Toshiaki ;
Aogi, Kenjiro ;
Naito, Yoichi ;
Matsubara, Nobuaki ;
Shigekawa, Takashi ;
Ueda, Shigeto ;
Takashima, Seiki ;
Hara, Fumikata ;
Yamashita, Tomonari ;
Ohwada, Shoichi ;
Sasaki, Yasutsuna .
CANCER SCIENCE, 2016, 107 (10) :1465-1470
[26]   A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer [J].
Nixon, N. A. ;
Hannouf, M. B. ;
Verma, S. .
EUROPEAN JOURNAL OF CANCER, 2018, 89 :72-81
[27]   Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy [J].
Burris, Howard A., III ;
Rugo, Hope S. ;
Vukelja, Svetislava J. ;
Vogel, Charles L. ;
Borson, Rachel A. ;
Limentani, Steven ;
Tan-Chiu, Elizabeth ;
Krop, Ian E. ;
Michaelson, Richard A. ;
Girish, Sandhya ;
Amler, Lukas ;
Zheng, Maoxia ;
Chu, Yu-Waye ;
Klencke, Barbara ;
O'Shaughnessy, Joyce A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) :398-405
[28]   Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer [J].
Gianni, Luca ;
Llado, Anna ;
Bianchi, Giulia ;
Cortes, Javier ;
Kellokumpu-Lehtinen, Pirkko-Liisa ;
Cameron, David A. ;
Miles, David ;
Salvagni, Stefania ;
Wardley, Andrew ;
Goeminne, Jean-Charles ;
Hersberger, Veronica ;
Baselga, Jose .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1131-1137
[29]   The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005) [J].
Duan, Fangfang ;
Zhong, Muyi ;
Ma, Yuyu ;
Song, Chenge ;
Zhang, Lehong ;
Lin, Ying ;
Wu, Zhiyong ;
Zhang, Yuanqi ;
Huang, Jiajia ;
Xu, Fei ;
Shi, Yanxia ;
Wang, Shusen ;
Yuan, Zhongyu ;
Xia, Wen ;
Bi, Xiwen .
BMC CANCER, 2022, 22 (01)
[30]   Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network [J].
Freedman, Rachel A. ;
Hughes, Melissa E. ;
Ottesen, Rebecca A. ;
Weeks, Jane C. ;
He, Yulei ;
Wong, Yu-Ning ;
Theriault, Richard ;
Keating, Nancy L. .
CANCER, 2013, 119 (04) :839-846
12345